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ABSTRACT 
Protein Arginine deiminases (PADs) play an important role in the pathogenesis of various 
diseases, including rheumatoid arthritis, multiple sclerosis, lupus, ulcerative colitis and breast 
cancer.  Therefore, the development of PAD-inhibitors has drawn significant research interest 
in recent years.  Herein, we describe the development of the first photoswitchable PAD-
inhibitors. These compounds possess an azobenzene photoswitch to optically control PAD 
activity.  Screening of a series of inhibitors structurally similar to BB-Cl-Amidine afforded 
compounds 1 and 2 as the most promising candidates for the light-controlled inhibition of 
PAD2; the cis-isomer of 1 is 10-fold more potent than its trans-isomer, whereas the trans-
isomer of 2 is 45-fold more potent than the corresponding cis-isomer.  The altered inhibitory 
potency upon photoisomerization has been confirmed in a competitive activity-based protein 
profiling (ABPP) assay.  Further investigations indicate that the trans-isomer of 2 is an 
irreversible inhibitor, whereas the cis-isomer acts as a competitive inhibitor.  In cells, the 
trans-isomer of compound 1 is completely inactive, whereas the cis-isomer inhibits histone 
H3-citrullination in a dose-dependent manner.  Taken together, 1 serves as the foundation for 
developing photopharmaceuticals that can be activated at the desired tissue, using light, to 
treat diseases where PAD activity is dysregulated. 
  
INTRODUCTION 
Protein arginine deiminases (PADs) are cysteine hydrolases that mediate the conversion of 
arginine to citrulline (Figure 1A).1,2  Five isozymes (PAD1, 2, 3, 4 and 6) are known but only 
four of them (PADs 1-4) are catalytically active.3  The deiminase activity of PADs 1-4 is 
strictly regulated by the presence of Ca2+ ions, and the holoenzymes are known to bind four 
(PAD1), five (PADs 3 and 4) and six (PAD2) calcium ions at distinct sites.4,5,6  Although 
calcium does not play a direct role in catalysis, recent crystal structures indicate that it 
induces a series of structural rearrangements that leads to the formation of the catalytically 
competent state.  Particularly, the movement of the nucleophilic cysteine (Cys647 and 
Cys645 in PAD2 and PAD4, respectively) into the active site is triggered by calcium.6   PAD-
mediated protein citrullination is known to regulate various cellular processes, including 
neutrophil extracellular trap (NET) formation, the epigenetic regulation of gene transcription, 
and the maintenance of pluripotency.  Moreover, aberrant protein citrullination is associated 
with various autoimmune diseases, including rheumatoid arthritis (RA), lupus, multiple 
sclerosis, ulcerative colitis, and certain cancers.1, 2, 7-14  
 Given the potential role of PADs in human pathology, the development of PAD 
inhibitors has attracted significant attention.1, 2, 15  The most widely-used pan-PAD inhibitor is 
Cl-amidine (Figure 2B), which possesses a chloroacetamidine warhead that mimics the 
substrate guanidinium and irreversibly inhibits the PADs.  Notably, Cl-amidine shows 
excellent efficacy in animal models of rheumatoid arthritis (RA), lupus, ulcerative colitis, 
spinal cord injury, breast cancer and atherosclerosis.13, 16-18  Structure-activity relationships 
ultimately led to the development of BB-Cl-amidine, a second-generation PAD inhibitor in 
which the phenyl and carboxamide groups of Cl-Amidine are replaced with a biphenyl and 
benzimidazole group, respectively (Figure 1B).17  BB-Cl-amidine exhibits at least 10-fold 
more potency than Cl-amidine in cell-based and animal experiments.17, 19, 20   However, the 
fluoroacetamidine counterparts of Cl-amidine and BB-Cl-amidine, i.e. F-Amidine and BB-F-
amidine, exhibit significantly less inhibitory activity, likely due to the lower electrophilicity 
of the fluoroacetamidine warhead (Figure 1B).21, 22  In agreement with the proposed 
mechanism of inhibition,23 the cocrystal structure of PAD4 bound to BB-F-amidine indicates 
that nucleophilic attack of the active site cysteine on the haloacetamidine warhead displaces 
the halide and irreversibly modifies the enzyme active site (Figure 1C).15  Recently, we 
showed that BB-F-Yne, an alkyne bearing fluoroacetamidine based PAD inhibitor, is 
remarkably selective for the PADs in cell based assays.24  By contrast, BB-Cl-yne, possesses 
a number of off targets including, β-tubulin, β-Actin, clathrin heavy chain 1 (CLTC), 
bifunctional glutamate/proline-tRNA ligase (EPRS), heterogeneous nuclear ribonucleoprotein 
U (HNRPU).24  These observations suggest that localized activation or deactivation of 
chloroacetamidine-containing inhibitors in the target tissue may be an alternative approach to 
limit potential systemic toxicities. 
 Photopharmacology, which relies on the activation or inactivation of drug molecules 
in the targeted tissue by light, has led to the development of several light-controlled ion-
channel blockers, receptor antagonists, antibiotics, and enzyme inhibitors.25-32  Light serves 
as a suitable external, noninvasive stimuli to modulate the potency of drug molecules and it 
can be delivered with high spatiotemporal precision and with a wide range of intensities as 
well as wavelengths.  Photopharmaceuticals are generally developed by incorporating 
photoresponsive groups into bioactive molecules.  The simplest and most widely-used 
example of such a photoresponsive element is an azobenzene.  Azobenzenes undergo a trans-
cis reversible isomerisation in the presence of light.  While the thermodynamically more 
stable trans-isomer can be switched to the less stable, bent cis-isomer by UV light (i.e., 350 
nm), the reverse process can be achieved by shining blue light (450 nm).29, 30  The excitation 
wavelengths and the half-life of the photoisomers can also be modulated by incorporating 
different substitutions on the azobenzene scaffold.  The two isomers of azobenzene mainly 
differ from each other in shape and polarity and consequently, they exhibit different 
biological activities.  Therefore, we hypothesized that the incorporation of azobenzene 
switches in BB-Cl-amidine, by replacing the biphenyl group, would result in a PAD-inhibitor 
that is structurally-similar to BB-Cl-amidine but can be activated or inactivated by light. 
Herein, we report the development of photoresponsive PAD inhibitors that can be used to 
optically control the inhibition of PADs in vitro and in cell-based assays. 
  
RESULTS AND DISCUSSION 
To achieve the optical control of PAD-activity, we synthesized various azobenzene-
containing compounds carrying either a fluoro- or chloroacetamidine warhead (compounds 1-
8, Scheme 1).  While compounds 1 and 2 are the simple azobenzene-modified analogues of 
BB-Cl-Amidine and BB-F-Amidine, respectively, compounds 3-8 carries various 
substitutions on the azobenzene as well as the benzimidazole moiety.  We hypothesized that 
the p-hydroxyl and p-dimethylamino substitutions on the terminal aromatic ring of the 
azobenzene moiety in compounds 3-6 may alter the binding affinity of different photoisomers 
for the enzyme active site by both electronic and steric influence.  The N-methyl and 4-
methoxy substitutions on the benzimidazole ring in compounds 7 and 8 were incorporated 
because we previously showed that these modifications significantly increase the potency and 
isoform-specificity of benzimidazole-based PAD inhibitors.15  The synthesis of compounds 
1-8 is depicted in Scheme 1 and it involves the common precursors 9 and 10, which were 
synthesized by following a previously reported procedure.15, 17 
 With this family of the photoresponsive PAD-inhibitors in hand, we next investigated 
their trans-cis isomerisation by UV-visible spectroscopy (Figure 2A and Figure S1).  The 
thermodynamically more stable trans-isomer of compound 1 (1T) exhibits maximal 
absorption (λmax) at 324 nm (Figure 2B).  However, upon irradiation with UV-A (λ = 320-380 
nm), this peak disappears with time, indicating the formation of the cis-isomer of this 
compound (i.e., 1C).  A plot of absorbance at 324 nm versus time indicates that 40-60 s of 
UV-A exposure is sufficient to convert more than 80 % of 1T into 1C (Figure 2C).  A similar 
phenomenon was also observed for the fluoroacetamidine warhead-containing compound 2 
(Figure 2D), indicating that the halogen substitution on the electrophilic warhead does not 
impact the photoisomerisation of compounds 1 and 2.  We also investigated the thermal 
stability of the cis-isomer by UV-vis spectroscopy, as fast back conversion to the trans-
isomer (from the thermodynamically less stable cis-isomer) would limit their utility.  Both 1C 
and 2C exhibit remarkable stability in aqueous buffer at 37 ⁰C as the change in absorbance at 
324 nm over 12 h is negligible after irradiating 1T or 2T with UV-A lamps (Figure 2E and 
Figure S2).  Both 1C and 2C can be switched back to their trans-form, i.e. 1T and 2T, 
respectively, by irradiating with blue light (λ = 400-450 nm) (Figure S1G and H) similarly to 
other azobenzene-containing photopharmaceuticals.25-32  This phenomenon, however, is not 
important for our purposes because compounds 1-8 are irreversible PAD-inhibitors and, as 
such, once the trans- or cis- isomer reacts with the active site cysteine, photoswitching will 
not turn off the inhibitor to regenerate the active enzyme.  The photoswitching properties of 
compounds 3-8 were also characterised by UV-vis spectroscopy (Figure S1) and the 
observations are in agreement with the reported photoswitching behaviour of hydroxy- and 
diaminomethyl-substituted azobenzene photopharmaceuticals.25-32 
 Having established the optimum photoswitching conditions (excitation wavelengths 
and exposure time), we set out to evaluate the inhibitory potency of the trans- (T) and cis- (C) 
isomers of the inhibitors in in vitro PAD-inhibition assays.  PADs 1-4 were expressed and 
purified following standard protocols established in the Thompson lab.4, 5  Inhibition of 
citrulline production was quantified using the COLDER assay (see experimental section). For 
PAD1, replacement of the biphenyl group in BB-Cl-amidine with the azobenzene decreases 
the potency of 1T by almost 8-fold, while the fluorinated analogue, 2T exhibits almost 6-fold 
higher activity than BB-F-amidine for this isozyme (Table 1).  Interestingly, compound 3T, 
with a p-hydroxy substitution, exhibits almost 13-fold higher activity than the unsubstituted 
analogue 1T, while the fluorinated analogue 4T exhibits 2-fold lower potency than 2T for 
PAD1.  Furthermore, compounds 5T, 7T and 8T are inactive towards PAD1 (Table 1), 
indicating that the p-dimethylamino substitution on the azobenzene in combination with the 
N-methyl and 4-methoxy substitutions on the benzimidazole ring disfavors binding of the 
inhibitor to the PAD1 active site.  Next, we evaluated the inhibitory potency of the cis-
isomers of 1-8.  The changes in the potency upon photoisomerisation of compounds 1-8 were 
generally found to be within 1-2-fold, although compound 6T exhibits 5-fold higher activity 
than 6C. 
 Next, we tested their ability to inhibit PAD3 and PAD4.  The potencies of the chloro- 
and fluoroacetamidine warhead-containing compounds 1-8 for PAD3-inhibition were 
generally found to be lower than BB-Cl-Amidine and BB-F-Amidine, respectively.  
Compound 3T exhibited the highest potency in the series towards PAD3 (Table 1).  
However, upon photoswitching to the cis-isomer (3C), there was no change in potency.  For 
other compounds in the series, photoisomerisation had modest (1.5-2-fold) effects on 
potency.  For PAD4, compounds 1T and 2T exhibit similar potency to BB-Cl-amidine and 
BB-F-amidine (Table 1).  As observed for PAD1 and PAD3, compound 3T exhibited the 
highest inhibitory activity towards PAD4, which is almost 2-fold higher than that of 1T. 
However, its fluorinated analogue, 4T, is only just as potent as compound 2T for PAD4 
inhibition.  While 5T (with a p-dimethylamino substitution) exhibits reasonable activity 
towards PAD4, the fluorinated analogue 6T is 5-fold less active (Table 1).  It should be noted 
that 5T is completely selective to PAD4 over PAD1 and PAD3, and such selectivity over 
PAD1 is rare in the literature.  However, compounds 7T and 8T exhibit poor inhibitory 
activity for PAD4, indicating that the benzimidazole-ring substitutions disfavor binding of the 
inhibitor to the active site of PAD4.  Similar to the inhibition of PAD1 and 3, the cis-
conformation of these compounds are equipotent to the trans-conformation, e.g. 2C (kinact/KI 
= 4150 ± 420 M-1min-1) inhibits PAD4 as well as 2T (kinact/KI = 3900 ± 1300 M
-1min-1). 
Moreover, there was only a two-fold change in potency between compounds 1T and 1C 
(Table 1). 
 Finally, we investigated the ability of these compounds to inhibit PAD2.  
Dysregulated PAD2 activity is strongly associated with multiple sclerosis, RA and breast 
cancer.1, 2  PAD2 is known to be secreted in the synovial fluid of arthritic joints, where it 
citrullinates numerous extracellular proteins, leading to the development of anticitrullinated 
protein antibodies (APCA), a diagnostic marker of RA.3, 12  PAD2 is also responsible for the 
citrullination of histone H3 at R26 position, which triggers the localized decondensation of 
chromatin and activates gene transcription.13, 33  Notably compound 1T is ~10-times less 
active than BB-Cl-amidine, indicating that replacement of the biphenyl group with the 
azobenzene disfavors interactions between the trans-form of the inhibitor and PAD2. 
Gratifyingly, its potency increases by 10-fold upon excitation to the cis-isomer, 1C (Table 1). 
Moreover, the kinact/KI value of 1C (6000 ± 680 M-1min-1) is almost identical to that of BB-
Cl-amidine (5000 M-1min-1).  The increased potency upon photoisomerisation is most likely 
due to enhanced binding to the PAD2 active site because the plots of kobs versus inhibitor 
concentration move from linear (1T) to hyperbolic (1C) (Figure 3A), indicative of a lower KI 
value for the cis-isomer.  The kinact and KI values for 1C are 0.15 min
-1 and 25.2 µM, 
respectively (Figure 3B).  These results indicate that the less potent compound 1T can be 
activated to the more potent compound 1C for the inhibition of PAD2 in the presence of UV-
A radiation.  Surprisingly, 2T, the fluorinated analogue of 1T, is almost 45-fold more active 
than its cis-isomer 2C (Table 1 and Figure 3C), indicating that the nature and size of the 
halogen atom in the haloacetamidine warhead plays an important role in the binding and 
reactivity of the inhibitor.  2T shows saturation kinetics with kinact and KI values of 0.3 min
-1 
and 66.4 µM, respectively (Figure S4C).  By contrast, 2C showed very little, if any, enzyme 
inactivation, as such a single kobs was used to estimate the kinact/KI of 2C (kinact/KI ≤ 100 ± 20 
M-1min-1) (Figure S4D).  In comparison to compounds 1 and 2, compounds 3C and 4C are ~ 
4- and 5-fold, respectively, more active than 3T and 4T, indicating that the p-hydroxy 
substitution in the azobenzene ring suppresses the optical control of the inhibition of PAD2 
activity (Table 1 and Figure 3C).  Compound 6T is also ~2-times more potent than 6C. 
Interestingly, 6C is ~57-, 20- and 23-fold more selective for PAD2 than PAD1, PAD3 and 
PAD4, respectively.  Such isozyme selectivity has rarely been observed amongst previously 
developed PAD inhibitors.  Furthermore, compound 8T is ~5-times more active than 8C, 
although the potency of 8T is very low (Table 1 and Figure 3C).  Taken together, compounds 
1 and 2 are the most promising candidates in the series for the optical control of PAD2 
activity – compound 1 can be photo-activated by 10-fold, whereas compound 2 can be photo-
deactivated by 45-fold. 
 To further confirm the results of our in vitro inhibition assays, we used a previously 
established competitive activity-based protein profiling (ABPP) assay to visualise the change 
in inhibitory potency upon photoisomerisation (Figure 4A and B).  For these studies, PAD2 
was treated with inhibitors in microplates for 30 min prior to the addition of rhodamine-
conjugated fluoroamidine (RFA), a PAD-targeted ABPP.  For strong inhibitors, RFA-
labelling will be blocked, whereas for weak inhibitor a smaller proportion of PAD2 would be 
occupied, and RFA-labelling is enhanced (Figure 4B). 
 Consistent, with the kinact/KI data, 1T is a very weak PAD2 inhibitor (Figure 4C); the 
IC50 is >100 µM.  By contrast, the IC50 of 1C, 9.1 µM, is more than 10-fold lower than that of 
1T.  Despite the fact that 2T is 45-fold more potent than 2C, these two isomers yielded 
similar IC50 values, i.e. 11.8 µM and 23.8 µM respectively, suggesting that 2T is only 2-times 
more active than 2C (Figure 4D).  To reconcile this contradiction, we considered the 
possibility that 2C binds to the PAD2 active site in such a conformation that precludes its 
reaction with C647, the active site cysteine, but still inhibits the enzyme reversibly.  To test 
this possibility, we determined the Km of Nα-benzoyl-L-arginine ethyl ester (BAEE), a known 
substrate of PAD2, in the presence of increasing concentrations of 2C.  The resulting 
inhibition patterns indicate that 2C is a reversible, competitive inhibitor, with a Ki value of 
25.2 µM (Figure S7).  Since 3C is almost 4-fold more potent than 3T (Table 1), we also 
assayed this compound in this competitive ABPP assay. Interestingly, the IC50 of 3C is >8-
fold lower than that of 3T, roughly in agreement with the results obtained using the COLDER 
assay. 
 Motivated by these promising inhibition data, we next evaluated their ability to inhibit 
histone H3 citrullination in cells; histone H3 is citrullinated at multiple positions, including 
R2, R8, R17 and R26 by PAD2.33-35  For these experiments, HEK293T/PAD2 overexpressing 
cells36, 37 were incubated with the inhibitor, CaCl2 and ionomycin (a calcium ionophore) for 3 
h, and then the cells were lysed, the soluble proteins in the lysate resolved by SDS-PAGE, 
and transferred to a PVDF membrane.  The membrane was then incubated with primary 
antibodies for histone H3 and citrullinated histone H3 (Cit 2, 8, 17), followed by incubation 
with appropriate secondary antibodies and imaged by Licor analysis.  Consistent with our in 
vitro data, 1T does not inhibit histone H3 citrullination even at 100 µM.  By contrast, the 
light-activated isomer 1C inhibits citrullination in a dose-dependent manner (Figure 5), 
suggesting that compound 1 can be photoactivated to inhibit histone H3-citrullination in 
HEK293T/PAD2 cells.  By contrast, 2T only showed modest inhibition (~33% at 100 µM) 
and 2C did not show any activity (Figure S8A).  Similarly, 3C was slightly more active than 
3T in inhibiting H3 citrullination by PAD2 (Figure S8B).  These results suggest that in 
addition to inhibitory potency, cell-permeability of the different isomers plays an important 
role in inhibiting PAD2 activity in the HEK293T/PAD2 cells. 
 We also evaluated the cytotoxicity of the photoisomers of compounds 1-3 and BB-Cl-
amidine in the HEK293T/PAD2 cells.  Compound 1, which exhibited the best results for the 
photoactivation of inhibition of PAD2 was as cytotoxic as BB-Cl-amidine (Figure S9). 
Notably, the trans- and cis isomers of 1 do not show any difference in the cytotoxicity, 
suggesting that the cytotoxicity of compound 1 does not originate from the inhibition of 
PAD2.  By contrast, compounds 2 and 3 are less toxic than 1. 
Conclusions 
Herein, we report the development of the first photoswitchable PAD inhibitor.  A series of 
compounds, 1-8, carrying an electrophilic warhead were evaluated and in vitro inhibition 
experiments indicate that these compounds can optically control PAD2 activity, with 1 and 2 
being the most promising candidates.  While the cis-isomer (1C) exhibits 10-fold higher 
potency than the trans-isomer (1T) of 1, the trans-isomer (2T) exhibits 45-fold more potency 
than the cis-isomer (2C) of 2.  Furthermore, alterations in the inhibitory potency upon 
photoisomerisation were confirmed using a competitive ABPP assay.  This study indicates 
that the IC50 of 1C is >10-fold lower than that of 1T.  In contrast to the kinact/KI data, 
compound 2C is only 2-fold less potent than 2T in the ABPP-based assay.  Detailed enzyme 
kinetics in the presence of increasing concentrations of 2C revealed that 2C is a reversible, 
competitive inhibitor of PAD2.  Cell-based studies reveal that 1T is inactive, whereas the 
light-activated isomer 1C inhibits histone H3 citrullination in a dose-dependent manner in 
HEK293T/PAD2 cells.   
In total, the present data sets a foundation for developing photopharmaceuticals to 
optically control PAD activity.  Nevertheless, further research is required to overcome the 
limitations of the current molecules, including the poor tissue penetration of 350 nm light and 
modest isozyme selectivity.  With regard to the former, introduction of fluoro- or chloro 
substitutions into the azobenzene scaffold will shift the excitation wavelength from UV to 
green or red light, respectively.38  With regard to the latter, the PADs generally show tissue or 
disease specific expression patterns.3  For example, PAD2 is overexpressed in luminal breast 
cancer cells and its expression correlates with the level of the HER2 protooncogene.13, 33  
Thus, compound 1 represents a promising starting point for the development of 
photopharmaceuticals against diseases in which PAD2 activity is dysregulated.  Nevertheless, 
improvements in potency and interisozyme selectivity will likely be necessary and could be 
achieved by modifying the chromophore.     
  
EXPERIMENTAL SECTION 
Materials and methods.  Fmoc-Orn(Boc)-OH was purchased from Chem-Impex 
International, Inc.  4-(phenylazo)benzoyl chloride, p-(p-dimethylaminophenylazo)benzoate 
dehydrate, DIPEA, anhydrous methanol, DMF, dichloromethane, piperidine, triethylamine, 
trifluoroacetic acid, chloroacetonitrile, fluoroacetonitrile and HPLC-grade acetonitrile were 
obtained from Sigma-Aldrich.  4'-Hydroxyazobenzene-4-carboxylic acid was bought from 
TCI Chemicals.  Precoated silica gel plates were purchased from Merck.  Deuterated solvents 
were acquired from Cambridge Isotope Laboratories.  Mouse monoclonal anti-histone H3 
(catalogue no. ab10799) and rabbit polyclonal anti-H3 (Citrulline R2, R8 and R17) (catalogue 
no. ab5103) were purchased from Abcam.  NMR spectra were recorded in d4-MeOH or d6-
DMSO as solvent.  1H and 13C NMR spectra were recorded using a Bruker 500 MHz NMR 
spectrometer.  Chemical shift values are cited with respect to SiMe4 as the internal standard.  
Column chromatography was carried out in glass columns.  Final compounds were purified 
by reverse-phase HPLC using a semi-preparative C18 column (Agilent, 21.2 × 250 mm, 10 
µm) and water/acetonitrile gradient supplemented with 0.05% trifluoroacetic acid. 
Synthesis.  Detailed procedures for the synthesis of compounds 1-8 are given in the 
supporting information.  All the compounds were isolated as trifluoroacetate salts and were 
characterized using 1H, 13C NMR spectroscopy and ESI-Mass spectrometry.  The purity of 
the compounds was analyzed by analytical HPLC. 
Inactivation kinetics.  Inactivation kinetic parameters for compounds 1-8 were determined 
by following reported procedures.22, 23  Briefly, PAD1, PAD2, PAD4 (2 µM) or PAD3 (5 
µM) was added to a prewarmed (10 min, 37 ⁰C) inactivation mixture (100 mM TRIS pH 7.4, 
50 mM NaCl, 10 mM CaCl2, 2 mM DTT, with a final volume of 50 µL) containing various 
concentrations of inhibitors. Aliquots (6 µL) of the inactivation mixture were removed at 
various time points and were added to a prewarmed (10 min, 37 ⁰C) reaction mixture (100 
mM TRIS pH 7.4, 50 mM NaCl, 10 mM CaCl2, 2 mM DTT, and 10 mM BAEE or 10 mM 
BAA for PAD3, with a final volume of 60 µL).  The reactions were quenched with liquid 
nitrogen after 15 min and citrulline production was quantified using the COLDER assay.5, 39 
The time-dependence of PAD inhibition was fit to equation 1, 
ν = ν0 e-kt                 (1), 
using Grafit, version 5.0.11, where ν is velocity, ν0 is initial velocity, k (or kobs is the pseudo-
first-order rate constant of inactivation, and t is the time.  If the rates of inactivation reached 
saturation, the concentration dependence of kobs was fit to equation 2, 
kobs = kinact [I] / (KI + [I])           (2), 
using Grafit, version 5.0.11, where kinact is the maximal rate of inactivation, KI is the 
concentration of inhibitor that yields half-maximal inactivation, and [I] is the concentration of 
inhibitor.  If the plot of kobs versus [I] did not saturate and was linear, then the value of 
kinact/KI was determined from the slope of the line.  All the experiments were carried out at 
least in duplicate. 
RFA-labelling.  The labeling of PAD2 with RFA in the presence of inhibitor was carried out 
by following a previously reported procedure.36, 40, 41  Briefly, PAD2 (2 µM final) was added 
to the reaction mixture (100 mM TRIS pH 7.4, 50 mM NaCl, 10 mM CaCl2, and 2 mM DTT 
in a final volume of 20 µL) containing DMSO or various concentrations of the inhibitor.  The 
mixture was incubated at 37 ⁰C for 30 min, followed by addition of RFA (10 µL, 2 µM final).  
Then the reaction mixture was incubated at 37 ⁰C for a further 2 h, quenched with 5X SDS-
PAGE dye, incubated at 95 ⁰C for 15 min and then loaded onto a 10% SDS-PAGE gel.  After 
electrophoresis, fluorescence of the protein bands was recorded using a typhoon scanner 
(excitation/emission maxima of ∼546/579, respectively).  Fluorescence intensity of the 
protein bands was quantified using ImageJ software and was plotted against the concentration 
of the inhibitor to obtain the IC50 values. 
Histone H3 Citrullination in HEK293TPAD2 Cells.  HEK293T cells stably expressing 
human PAD2 (HEK293T/PAD2) were cultured as reported earlier.36, 37  Cells were grown to 
~90% confluence, trypsinized, quenched with complete media and harvested by 
centrifugation at 3,000 rpm for 3.5 min.  Then the cells were washed with 1X HBS four times 
and were resuspended in 1X HBS at 8 × 106 cells/mL.  4 × 105 cells were used for subsequent 
assays with each inhibitor concentration.  Calcium chloride (1 mM), ionomycin (10 µM), and 
either DMSO or various concentrations of inhibitor were incubated with the cells for 3 h.  
The final concentration of DMSO in each sample was 1%.  Triton X-100 (1% final) was then 
added to each sample and the suspension was sonicated at 4 ⁰C for 1 h, followed by 
centrifugation at 21,000g for 15 min.  Lysates were collected, soluble proteins in the lysates 
were quantified using the DC-assay (Bio-Rad) and were normalized.  2 µg of protein was 
loaded onto a 4-15% gradient SDS-PAGE gel, separated by electrophoresis and proteins were 
then transferred to PVDF membrane (Bio-Rad) at 80 V for 50 min.  The membrane was then 
blocked by treating with phosphate buffered saline containing 0.1% Tween-20 (PBST) and 
5% BSA, and the blocked membrane was incubated with primary antibodies for histone H3 
(1:1,000) and histone H3Cit 2,8,17 (1:1000) in PBST with 5% BSA for 12 h at 4 ⁰C.  After 
washing the membrane with PBST, it was incubated with anti-mouse and anti-rabbit IgG 
Licor conjugate (1:5000) in PBST and 5% BSA for 1 h at 25 ⁰C.  The membrane was then 
washed with PBST and imaged by Licor analysis. 
Cytotoxicity Studies. HEK293T/PAD2 cells were plated (2 × 104 cells/well) in a 96-well 
plate and were allowed to grow for 24 h.  DMSO or various concentrations of inhibitor were 
added to the wells and incubated for 24 h.  Cell viability was measured using the XTT 
reagent kit (ATCC) by recording the absorbance at 475 nm and 660 nm.  An eight-point 
dose-response curve was fit to the following equation 3 using GraphPad Prism 7.03 to 
determine the EC50 values for cell-growth inhibition, 
Y = Bottom + (Top-Bottom) / [1 + 10((logEC50-X)*Hillslope)]              (3), 
where Top and Bottom are plateaus of the dose-response curve, X is the log of inhibitor-
concentration, Hillslope is the slope factor or Hill slope. 
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Table 1. kinact/KI vales for the inhibition of PADs 1-4 by BB-Cl-Amidine, BB-F-Amidine, and 
trans- (T) and cis- (C) isomers of compounds 1-8 (see Scheme 1 for variable groups). 
Compounds & 
photoisomers 
kinact/KI (M-1min-1) 
PAD1 PAD2 PAD3 PAD4 
BB-Cl-Amidine 16000a 5000a 6000a 14000a 
BB-F-Amidine 900a 1200a 3400a 3750a 
1 T 2300 ± 200
b 600 ± 30b 1000 ± 60b 10510 ± 590c 
C 2000 ± 100b 5970 ± 670c 1500 ± 40b 4900 ± 100b 
2 T 4920 ± 760
c 4520 ± 760c 500 ± 77b 3880 ± 1320c 
C 2850 ± 320c ≤100 ± 20de 1100 ± 40b 4150 ± 420c 
3 T 28770 ± 7020
c 2100 ± 100b 6500 ± 100b 19920 ± 2170c 
C 12000 ± 570c 7330 ± 1280c 6300 ± 400b 27940 ± 180c 
4 T 2130 ± 510
c 900 ± 40b 2020 ± 210c 3640 ± 100c 
C 1030 ± 380c 4410 ± 980c 1300 ± 50b 5580 ± 350c 
5 T No Inhibition 230 ± 70
d No Inhibition 2440 ± 760c 
C No Inhibition ≤100 ± 40d No Inhibition 3070 ± 50c 
6 T 870 ± 360
c 4340 ± 650c 350 ± 50d 450 ± 40d 
C 180 ± 70d 10490 ± 1460c 510 ± 50d 450 ± 40d 
7 
T ≤40 ± 10d ≤100 ± 30d ≤130 ± 30d 600 ± 30b 
C ≤80 ± 30d 220 ± 30d 170 ± 20d 600 ± 100b 
8 
T No Inhibition 360 ± 100d No Inhibition ≤60 ± 20d 
C No Inhibition 80 ± 40d No Inhibition ≤80 ± 20d 
akinact/KI values were taken from the published results (ref. 15). 
bkinact/KI was determined from 
a linear fit of the kobs versus [I] data. ckinact and KI was determined from a nonlinear fit of the 
kobs versus [I] data. 
dA single kobs was determined.  eDetailed kinetic studies indicate that 2C is 
actually a reversible inhibitor of PAD2 with a Ki value of 25.2 µM (see Figure S7). 
 
  
SCHEME LEGENDS 
 
Scheme 1. Chemical structures and the synthesis of compounds 1-8. 
 
FIGURE LEGENDS 
 
Figure 1. (A) PAD-catalyzed citrullination of peptidyl-arginine. (B) Chemical structures of 
pan-PAD inhibitors and the kinact/KI values for BB-Cl-Amidine. (C) Cocrystal structure of 
PAD4 bound to BB-F-Amidine indicating the covalent modification of Cys645 by the 
inhibitor (PDB code 5N0M).15 
 
Figure 2. (A) The chemical structures of trans- and cis-isomers of compounds 1-8 (see 
Scheme 1 for variable groups). (B) The change in the UV-vis spectra of compound 1 upon 
irradiation with UV-A, demonstrating the photoisomerization of 1T into 1C. (C) 
Optimisation of UVA-exposure time from the change in absorbance of 1 at 324 nm. (D) 
Photoisomerization of compound 2 monitored by UV-Vis spectra. (E) Thermal stability of 
1C in aqueous buffer at 37 ⁰C.  Assay conditions: compound 1 (30 µM), 100 mM TRIS pH 
7.4, 50 mM NaCl. 
 
Figure 3. Concentration dependence of pseudo-first-order rate constant of inactivation (kobs) 
of PAD2 by 1T (A) and 1C (B). (C) Potencies (kinact/KI) of trans- and cis-isomers of 
compounds 1-8 for the inhibition of PAD2.  Assay conditions: PAD2 (2 µM), 100 mM TRIS 
pH 7.4, 50 mM NaCl, 2 mM DTT, 10 mM CaCl2, and 10 mM BAEE. 
 
Figure 4. (A) Chemical structure of RFA. (B) Workflow of labelling of PAD2 with RFA in 
the presence of inhibitors.  RFA-labelling of PAD2 in the presence of 1T and 1C (C), 2T and 
2C (D), 3T and 3C (E). F and C stands for fluorograph and coomassie stain, respectively.  
Concentrations of inhibitors [I] are given in micromolar (µM).  Intensities of each band in the 
fluorograph were measured using ImageJ software and the relative decrease in the 
fluorescence intensity has been plotted against the concentration of inhibitor to obtain the 
IC50 values.  Assay conditions: PAD2 (2 µM), 100 mM TRIS pH 7.4, 50 mM NaCl, 2 mM 
DTT, and 10 mM CaCl2. 
 
Figure 5.  Inhibition of histone H3 citrullination in HEK293T/PAD2 cells by compound 1. 
Inhibitor concentrations [I] are given under each lane of the western-blot image.  Citrullinated 
H3 (H3Cit) and H3 are shown in red and green, respectively. Quantification of each band 
yielded the H3Cit/H3 ratio, from which the % relative H3 citrullination was calculated. 
 
 
 
